ORCHID: A phase II study of Olaparib in Metastatic Renal Cell Carcinoma Patients HarborIng a BAP1 or Other DNA Repair Gene Mutations

BACKGROUND: DNA damage repair genes alterations (DDRa) are frequent events in renal cell carcinoma (RCC), including BAP1 and other DDRa. Olaparib is a poly ADP ribose polymerase inhibitor (PARPi) that is FDA-approved for the treatment of several malignancies with DDRa. Preclinical models demonstrate...

Descripción completa

Detalles Bibliográficos
Autores principales: Ged, Georges, Rifkind, Irina, Tony, Lori, Daugherty, Keegan, Michalik, Amber, Wang, Hao, Carducci, Michael, Markowski, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Oral Abstract Presentations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445572/
http://dx.doi.org/10.1093/oncolo/oyad216.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445572/
http://dx.doi.org/10.1093/oncolo/oyad216.002

Ejemplares similares